STOCK TITAN

QuidelOrtho (QDEL) CFO amends trust share purchase pricing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an amended insider transaction reflecting an open-market purchase of 3,370 shares of common stock on February 13, 2026, acquired indirectly through a trust at a weighted average price of $23.6623 per share.

The amendment corrects the pricing details, noting a purchase price range from $23.0150 to $23.6750 per share. Following these transactions, Busky’s indirect holdings held by a trust total 10,290 shares, and his direct ownership stands at 41,412 shares of QuidelOrtho common stock.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Busky Joseph M.

(Last) (First) (Middle)
9975 SUMMERS RIDGE ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
02/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2026 P 3,370 A $23.6623(1) 10,290 I By Trust
Common Stock 41,412 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Form 4 originally filed on February 13, 2026 is being amended to report the correct pricing of the shares purchased by the Reporting Person. The weighted average purchase price of these transactions was $23.6623 per share, with a range of $23.0150 to $23.6750 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price.
Remarks:
/s/ Phillip S. Askim, attorney-in-fact for Joseph M. Busky 02/19/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did QuidelOrtho (QDEL) disclose in this Form 4/A?

QuidelOrtho disclosed that CFO Joseph M. Busky indirectly bought 3,370 shares of common stock through a trust. The open-market purchase occurred on February 13, 2026, and the filing amends prior pricing details while confirming his updated direct and indirect share ownership levels.

At what price did the QuidelOrtho (QDEL) CFO buy the 3,370 shares?

The 3,370 QuidelOrtho shares were purchased at a weighted average price of $23.6623 per share. The amended filing states the individual trade prices ranged from $23.0150 to $23.6750, and notes that full breakdowns can be provided upon request to interested parties.

How many QuidelOrtho (QDEL) shares does the CFO own after this transaction?

After this transaction, CFO Joseph M. Busky indirectly owns 10,290 QuidelOrtho shares through a trust. His direct ownership is 41,412 shares of common stock, giving investors a clearer view of his total reported economic exposure to the company’s equity.

Why was this QuidelOrtho (QDEL) Form 4/A filed as an amendment?

The Form 4/A was filed to correct the pricing information for the previously reported share purchases. It clarifies that the weighted average price was $23.6623, with trades executed between $23.0150 and $23.6750, replacing the initial, incorrect pricing disclosure made earlier.

Was the QuidelOrtho (QDEL) CFO purchase a direct or indirect holding?

The 3,370 purchased shares are reported as an indirect holding by a trust associated with CFO Joseph M. Busky. The filing distinguishes these from his separately reported direct ownership position, which totals 41,412 shares of QuidelOrtho common stock after the reported date.

What additional pricing details are available from this QuidelOrtho (QDEL) insider trade?

The filing notes that detailed trade-level pricing information, including the number of shares at each price within the $23.0150 to $23.6750 range, is available upon request. Interested security holders, the issuer, or SEC staff may obtain a full transaction breakdown from the reporting person.
Quidel

NASDAQ:QDEL

QDEL Rankings

QDEL Latest News

QDEL Latest SEC Filings

QDEL Stock Data

1.60B
66.77M
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
SAN DIEGO